In addition, intrathecal injection of GLP-1 receptor agonists GLP-1 and exenatide potently alleviate formalin-, peripheral nerve injury-, bone cancer-, and diabetes-induced hypersensitivity in rats [48]. This evidence concerns the gene GLP1R and bone neoplasm.